Celldex Therapeutics, Inc. Revenues
Celldex Therapeutics, Inc. (CLDX) reported Revenues of $1.76 million for the 3-month period ending 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2019-03-07
- Celldex Therapeutics, Inc. revenues for the quarter ending 2018-12-31 was $1.76M, a 48.96% decline year-over-year.
- Celldex Therapeutics, Inc. revenues for the quarter ending 2018-09-30 was $941.00K, a 76.02% decline year-over-year.
- Celldex Therapeutics, Inc. revenues for the quarter ending 2018-06-30 was $2.76M, a 27.84% decline year-over-year.
- Celldex Therapeutics, Inc. revenues for the quarter ending 2018-03-31 was $4.07M, a 165.19% increase year-over-year.
- Celldex Therapeutics, Inc. revenues for fiscal 2017 was $12.74M, a 87.78% increase from fiscal 2016.
- Celldex Therapeutics, Inc. revenues for fiscal 2016 was $6.79M, a 23.83% increase from fiscal 2015.
- Celldex Therapeutics, Inc. revenues for fiscal 2015 was $5.48M, a 52.82% increase from fiscal 2014.
- Celldex Therapeutics, Inc. revenues for fiscal 2014 was $3.59M, a 12.77% decline from fiscal 2013.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2018-12-31 | $1.76M 10-K · filed 2019-03-07 | $2.71M derived: sum of 2 quarters · filed 2019-03-07 | $5.47M derived: sum of 3 quarters · filed 2019-03-07 | $9.54M derived: sum of 4 quarters · filed 2019-03-07 |
| 2018-09-30 | $941.00K 10-K · filed 2019-03-07 | $3.70M derived: sum of 2 quarters · filed 2019-03-07 | $7.77M derived: sum of 3 quarters · filed 2019-03-07 | $11.23M derived: sum of 4 quarters · filed 2019-03-07 |
| 2018-06-30 | $2.76M 10-K · filed 2019-03-07 | $6.83M derived: sum of 2 quarters · filed 2019-03-07 | $10.29M derived: sum of 3 quarters · filed 2019-03-07 | $14.21M derived: sum of 4 quarters · filed 2019-03-07 |
| 2018-03-31 | $4.07M 10-K · filed 2019-03-07 | $7.52M derived: sum of 2 quarters · filed 2019-03-07 | $11.45M derived: sum of 3 quarters · filed 2019-03-07 | $15.28M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-12-31 | $3.46M 10-K · filed 2019-03-07 | $7.38M derived: sum of 2 quarters · filed 2019-03-07 | $11.21M derived: sum of 3 quarters · filed 2019-03-07 | $12.74M 10-K · filed 2018-03-07 |
| 2017-09-30 | $3.92M 10-K · filed 2019-03-07 | $7.75M derived: sum of 2 quarters · filed 2019-03-07 | $9.29M 10-Q · filed 2017-11-07 | $11.16M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $3.83M 10-K · filed 2019-03-07 | $5.36M 10-Q · filed 2017-08-08 | $7.24M derived: sum of 3 quarters · filed 2019-03-07 | $9.46M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $1.53M 10-K · filed 2019-03-07 | $3.41M derived: sum of 2 quarters · filed 2019-03-07 | $5.63M derived: sum of 3 quarters · filed 2019-03-07 | $7.02M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $1.87M 10-K · filed 2018-03-07 | $4.09M derived: sum of 2 quarters · filed 2018-03-07 | $5.48M derived: sum of 3 quarters · filed 2018-03-07 | $6.79M 10-K · filed 2018-03-07 |
| 2016-09-30 | $2.22M 10-K · filed 2018-03-07 | $3.61M derived: sum of 2 quarters · filed 2018-03-07 | $4.91M 10-Q · filed 2017-11-07 | $6.70M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | $1.39M 10-K · filed 2018-03-07 | $2.69M 10-Q · filed 2017-08-08 | $4.48M derived: sum of 3 quarters · filed 2018-03-07 | $5.51M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | $1.30M 10-K · filed 2018-03-07 | $3.09M derived: sum of 2 quarters · filed 2018-03-07 | $4.12M derived: sum of 3 quarters · filed 2018-03-07 | $6.30M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | $1.79M 10-K · filed 2017-03-14 | $2.82M derived: sum of 2 quarters · filed 2017-03-14 | $4.99M derived: sum of 3 quarters · filed 2017-03-14 | $5.48M 10-K · filed 2018-03-07 |
| 2015-09-30 | $1.03M 10-K · filed 2017-03-14 | $3.20M derived: sum of 2 quarters · filed 2017-03-14 | $3.69M 10-Q · filed 2016-11-07 | $5.17M derived: sum of 4 quarters · filed 2017-03-14 |
| 2015-06-30 | $2.18M 10-K · filed 2017-03-14 | $2.66M 10-Q · filed 2016-08-08 | $4.14M derived: sum of 3 quarters · filed 2017-03-14 | $5.24M derived: sum of 4 quarters · filed 2017-03-14 |
| 2015-03-31 | $486.00K 10-K · filed 2017-03-14 | $1.96M derived: sum of 2 quarters · filed 2017-03-14 | $3.06M derived: sum of 3 quarters · filed 2017-03-14 | $3.66M derived: sum of 4 quarters · filed 2017-03-14 |
| 2014-12-31 | $1.48M 10-K/A · filed 2016-02-25 | $2.58M derived: sum of 2 quarters · filed 2016-02-25 | $3.17M derived: sum of 3 quarters · filed 2016-02-25 | $3.59M 10-K · filed 2017-03-14 |
| 2014-09-30 | $1.10M 10-K/A · filed 2016-02-25 | $1.69M derived: sum of 2 quarters · filed 2016-02-25 | $2.11M 10-Q · filed 2015-11-05 | $2.73M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $592.00K 10-K/A · filed 2016-02-25 | $1.01M 10-Q · filed 2015-08-10 | $1.63M derived: sum of 3 quarters · filed 2016-02-25 | $2.61M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $416.00K 10-K/A · filed 2016-02-25 | $1.04M derived: sum of 2 quarters · filed 2016-02-25 | $2.02M derived: sum of 3 quarters · filed 2016-02-25 | $2.11M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $620.00K 10-K · filed 2015-02-24 | $1.60M derived: sum of 2 quarters · filed 2015-02-24 | $1.70M derived: sum of 3 quarters · filed 2015-02-24 | $4.11M 10-K/A · filed 2016-02-25 |
| 2013-09-30 | $980.00K 10-K · filed 2015-02-24 | $1.08M derived: sum of 2 quarters · filed 2015-02-24 | $3.49M 10-Q · filed 2014-11-05 | $7.14M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $97.00K 10-K · filed 2015-02-24 | $2.51M 10-Q · filed 2014-08-07 | $6.16M derived: sum of 3 quarters · filed 2015-02-24 | $9.27M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $2.41M 10-K · filed 2015-02-24 | $6.06M derived: sum of 2 quarters · filed 2015-02-24 | $9.17M derived: sum of 3 quarters · filed 2015-02-24 | $11.18M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | $3.65M 10-K · filed 2014-03-03 | $6.76M derived: sum of 2 quarters · filed 2014-03-03 | $8.77M derived: sum of 3 quarters · filed 2014-03-03 | $11.20M 10-K · filed 2015-02-24 |
| 2012-09-30 | $3.11M 10-K · filed 2014-03-03 | $5.12M derived: sum of 2 quarters · filed 2014-03-03 | $7.55M 10-Q · filed 2013-11-08 | $9.99M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-06-30 | $2.01M 10-K · filed 2014-03-03 | $4.44M 10-Q · filed 2013-08-06 | $6.88M derived: sum of 3 quarters · filed 2014-03-03 | $9.24M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-03-31 | $2.43M 10-K · filed 2014-03-03 | $4.87M derived: sum of 2 quarters · filed 2014-03-03 | $7.23M derived: sum of 3 quarters · filed 2014-03-03 | $9.18M derived: sum of 4 quarters · filed 2014-03-03 |
| 2011-12-31 | $2.43M 10-K · filed 2013-03-08 | $4.80M derived: sum of 2 quarters · filed 2013-03-08 | $6.75M derived: sum of 3 quarters · filed 2013-03-08 | $9.27M 10-K · filed 2014-03-03 |
| 2011-09-30 | $2.36M 10-K · filed 2013-03-08 | $4.32M derived: sum of 2 quarters · filed 2013-03-08 | $6.83M 10-Q · filed 2012-11-02 | $44.55M derived: sum of 4 quarters · filed 2013-03-08 |
| 2011-06-30 | $1.95M 10-K · filed 2013-03-08 | $4.47M 10-Q · filed 2012-08-09 | $42.19M derived: sum of 3 quarters · filed 2013-03-08 | $44.60M derived: sum of 4 quarters · filed 2013-03-08 |
| 2011-03-31 | $2.52M 10-K · filed 2013-03-08 | $40.24M derived: sum of 2 quarters · filed 2013-03-08 | $42.65M derived: sum of 3 quarters · filed 2013-03-08 | $45.60M derived: sum of 4 quarters · filed 2013-03-08 |
| 2010-12-31 | $37.72M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | $40.13M derived: sum of 2 quarters · filed 2013-03-08 | $43.08M derived: sum of 3 quarters · filed 2013-03-08 | $46.79M 10-K · filed 2013-03-08 |
| 2010-09-30 | $2.41M 10-Q · filed 2011-11-03 | $5.36M derived: sum of 2 quarters · filed 2011-11-03 | $9.07M 10-Q · filed 2011-11-03 | |
| 2010-06-30 | $2.95M 10-Q · filed 2011-08-04 | $6.66M 10-Q · filed 2011-08-04 | ||
| 2009-12-31 | $15.18M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |